The Role of a Motion Sensor With Accompanying Web Application on Step Counts, Energy Balance, and Metabolic Markers in Nurses

Not Applicable

Completed

• Conditions: Cardiovascular Risk Factor; Cardiovascular Diseases

• Registration Number: NCT04524572
• Lead Sponsor: Ottawa Heart Institute Research Corporation

Brief Summary

The purpose of this prospective randomized controlled trial is to explore the role of a motion sensor with accompany web application on step counts, energy balance, and metabolic markers in nurses. Additionally, eating behaviours, behavioural regulation in exercise, and mood states that may impact these parameters will also be examined.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11-26
• Primary Completion: 2014-04-25
• Study Completion: 2015-08-01
• Study First Submitted: 2020-08-19
• Study First Submitted QC: 2020-08-21
• Study First Posted: 2020-08-24
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-01
• Last Update Posted: 2023-09-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

• 1. Participant must be a registered nurse with the University of Ottawa Heart Institute;

  2. Participant must be 18 years of age or older;

  3. Participant must be able to walk unassisted;

  4. Participant is able and willing to provide informed consent.

Exclusion Criteria

1. Participant is pregnant, lactating or planning to become pregnant during the study period;
2. Participant is unable to read and understand English;
3. Medical contraindications to exercise;
4. Already using a motion sensor device to track physical activity. -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Step counts	6 weeks during observation and 6 weeks during intervention	All participants will be asked to wear a Tractivity® motion sensor device on their ankle for to assess their daily step count and physical activity energy expenditure

Secondary Outcome Measures

Name	Time	Method
Body Mass (kg)	Screening (week 1), Observation (weeks 2-5), during the intervention (weeks 6-9), post study at week 26 and week 52	Body weight will be measured using a digital scale to the nearest 0.1 kilogram
Waist Circumference	Screening (week 1), Observation (weeks 2-5), during the intervention (weeks 6-9), post study at week 26 and week 52	Waist circumference will be measured using a tape measure
Fat mass	Screening (week 1), Observation (weeks 2-5), during the intervention (weeks 6-9), post study at week 26 and week 52	Fat mass will be measured using bioelectrical impedance analysis

Trial Locations

Locations (1)

University of Ottawa Heart Institute; 🇨🇦 Ottawa, Ontario, Canada